Dergiler / art / 2014 / Cilt: 29 - Sayı: 3

The off-label use of rituximab for the management of ınflammatory disorders: American university of beirut medical center experience

Dergi
art
Sayfa
194–202
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: The off-label use of rituximab in various inflammatory diseases showed improvement in symptoms with no significant side effects in patients who have failed previous treatment with multiple conventional regimens.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to evaluate the efficacy of off-label use of rituximab with possible side effects.
📊
Temel Bulgular & Veri:Patients and methods: Records of the 44 American University of Beirut Medical Center pharmacies were searched for patients who used rituximab over the past 4.5 years, and data on rituximab dosage, protocol and side effects were documented.
💡
Sonuç & Katkı:Conclusion: The off-label use of rituximab in various inflammatory diseases showed improvement in symptoms with no significant side effects in patients who have failed previous treatment with multiple conventional regimens.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: This study aims to evaluate the efficacy of off-label use of rituximab with possible side effects. Patients and methods: Records of the 44 American University of Beirut Medical Center pharmacies were searched for patients who used rituximab over the past 4.5 years, and data on rituximab dosage, protocol and side effects were documented. The majority of patients had systemic lupus erythematosus. Autoimmune thrombocytopenic purpura, antiphospholipid syndrome, Sjögren's syndrome, Wegener’s granulomatosis, autoimmune hemolytic anemia, dermatomyositis, and pemphigus vulgaris were also reported. Outcome measures were improvement in signs and symptoms during a follow-up period of two years. Results: Twenty-nine out of the 44 patients had complete response without relapse. Of those, 12 patients were in remission after the first cycle. Of the systemic lupus erythematosus cases, 12 had complete response without relapse; of which, five patients had remission after the first cycle. No significant toxicities were noted. Conclusion: The off-label use of rituximab in various inflammatory diseases showed improvement in symptoms with no significant side effects in patients who have failed previous treatment with multiple conventional regimens.

🔖

Bu Makaleye Atıf Yap

HARB, D., MOUKADEM, H., MASRI, A. F., SALEM, Z., TAHER, A., UTHMAN, I., NAYFE, R., MEHDI, A. (2014). The off-label use of rituximab for the management of ınflammatory disorders: American university of beirut medical center experience. art, Cilt: 29 - Sayı: 3, 194–202. https://ajindex.com/articles/205003

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor- alpha treatment. J Rheumatol 2005;32:2109-15
  2. Cohen Tervaert JW. Rituximab in ANCA-associated vasculitis: a revolution? Nephrol Dial Transplant 2011;26:3077-9
  3. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006;185:544-8
  4. Butterly SJ, Pillans P, Horn B, Miles R, Sturtevant J. Off-label use of rituximab in a tertiary Queensland hospital. Intern Med J 2010;40:443-52
  5. Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther 2007;20:277-87
  6. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009;18:767-76
  7. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010;29:707-16
  8. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ; BIOGEAS STUDY Group. A systematic review of the off- label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008;87:345-64
  9. Calero I, Sanz I. Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med 2010;10:416-24
  10. Quintero OL, Amador-Patarroyo MJ, Montoya- Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun 2012;38:J109-19
  11. Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev 2012;11:A386-92
  12. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
  13. Abstracts of the Third Meeting of West European Societies of Biological Psychiatry. June 2-4, 2010. Berlin, Germany. Eur Arch Psychiatry Clin Neurosci 2010;260 Suppl 1:S3-74
  14. Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med 200